MRC1 and glioma: Thus, it was reported that MMR deficiency does not lead to clinical resistance to TMZ in gliomas [158], while a study published later showed that even small changes in the expression of MSH2 have an influence on TMZ sensitivity and thus, the therapeutic success [159].